Published Aug 08, 2018

Harbour BioMed inks $350 million deal for rights to A167

Member News
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167

Related or similar articles

April 14, 2019

Global 3D Printed Drugs Market Insights 2019-2024 : Extend Biosciences, Bioduro, Affinity Therapeutics

One of the dominating players in the 3D Printed Drugs market is Extend Biosciences
Member News
June 18, 2024

Labshares Announces Key Leadership Additions: Devon Lagasse Joins as VP of Growth and Emma Orfanos Is Promoted to Manager of Business Development

Press Releases
October 31, 2018

Labshares Newton Launches Near Capacity and Announces Expansion Plans

Labshares Newton, an office and laboratory incubator for emerging biotechnology and life science companies, announced the launch of its first location in Newton.
Press Releases